A phase II trial of ipilimumab, nivolumab, or ipilimumab and nivolumab with or without azacitidine in relapsed or refractory myelodysplastic neoplasms

Affiliations

• ¹ The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
• ² The University of Texas MD Anderson Cancer Center, Department of Hematopathology, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
• ³ The University of Texas MD Anderson Cancer Center, Department of Biostatistics, 1515 Holcombe Blvd., Houston, TX, 77030, USA.
• ⁴ The University of Texas MD Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd., Houston, TX, 77030, USA. ggarciam@mdanderson.org.